Proviron 25mg/tab 50 Tabletten by Magnus Pharmaceuticals

Usage

1. Calculate your total protocol length first — determine whether your suppression history calls for a 4-week, 6-week, or 8-week framework before selecting a dose schedule.
2. Begin the loading phase on day 1 of PCT: take two 25 mg tablets (50 mg total) in the morning with a small meal to optimise GI tolerance.
3. Run labs at the end of week 3 — total testosterone, free testosterone, LH, and FSH — and use results to confirm whether to maintain 50 mg, step down to 25 mg, or extend the loading phase.
4. Enter the maintenance phase at the dose indicated by your week-3 panel, holding steady alongside your SERM until the week-6 checkpoint.
5. Initiate the taper at week 7: reduce to one 25 mg tablet daily for five days, then shift to alternate-day 25 mg dosing for the final week before stopping.
6. Take a final blood panel 10–14 days after the last tablet to verify that free and total testosterone, LH, and FSH have returned to pre-cycle baseline ranges before closing out the protocol.

Warnings

Frequently asked questions

How should mesterolone be dosed across the different phases of a PCT protocol?

A phased approach works best: start at 50 mg daily during the first two weeks to saturate SHBG binding sites rapidly, hold at 25–50 mg through the mid-protocol maintenance window alongside your SERM, then step down to 25 mg daily and finally alternate-day dosing in the final week. This graduated structure prevents abrupt androgenic withdrawal and mirrors the gradual rise of endogenous testosterone production.

What factors determine how long a mesterolone PCT protocol should run?

Three variables set protocol length: the degree and duration of androgen suppression from the preceding cycle, the class of compounds used (oral-only versus esterified injectables), and the individual's pre-cycle hormonal baseline. Heavier or longer suppression requires a longer maintenance phase before any taper starts. Blood panel results at weeks 3 and 6 provide the objective data to decide whether to extend, maintain, or begin the step-down.

Should mesterolone dose be tapered at the end of PCT, or stopped abruptly?

Gradual tapering is strongly preferred over abrupt cessation. Stopping mesterolone suddenly can allow SHBG levels to rebound before endogenous testosterone is fully established, temporarily reducing free androgen availability. A step-down from 50 mg to 25 mg daily, then to alternate-day 25 mg over the final week, allows SHBG to re-equilibrate progressively alongside recovering endogenous output.

Why is the 25 mg per tablet concentration of Magnus Proviron the highest single-tablet dose in the mesterolone product group?

At 25 mg per tablet, Magnus Pharmaceuticals' Proviron delivers the maximum per-unit mesterolone concentration available as a single tablet in this product range. This means a standard 50 mg loading dose requires only two tablets — no splitting — while the 25 mg maintenance or taper dose is a clean single-tablet unit. HPLC potency testing per batch confirms each tablet hits the declared API concentration.

How does the 50-tablet pack size align with a structured eight-week PCT dosing schedule?

The 50-tablet pack maps precisely to an eight-week phased protocol: two tablets daily for two weeks (28 tablets), one tablet daily for four weeks (28 tablets) — totalling 56 tablets — with the remaining supply used for alternate-day taper dosing in the final week. This near-exact fit means one pack covers the full protocol without requiring a partial second order mid-recovery. (2) angle_used

Manufacturer

Magnus Pharmaceuticals approaches tablet formulation for its oral PCT product line through a compound-specific content-uniformity engineering framework — and for Mesterolone 25 mg/tab, the critical production variable is consistent per-tablet API distribution across every unit in the 50-tablet batch. At 25 mg API per tablet, achieving acceptable uniformity requires validated granulation sequences, defined mixing dwell times, and mandatory in-process sampling at compression intervals. Released batches carry instrument-derived HPLC potency documentation that ties each lot's per-tablet API figure to the specific analytical run that generated it — not to a generic specification range applied across product families. Endotoxin burden is assessed by LAL (Limulus Amebocyte Lysate) testing and documented in the batch release dossier, providing an independent biological safety checkpoint separate from chemical potency verification. This dual-checkpoint release architecture — content uniformity confirmed chemically, endotoxin burden assessed biologically — reflects Magnus Pharmaceuticals' compound-specific quality commitment for its oral androgen dosage forms.